Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.

ABSTRACT: [This corrects the article DOI: 10.1371/journal.pone.0222658.].

SUBMITTER: de Jong LA 

PROVIDER: S-EPMC8970364 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature